Jakub Svoboda, MD, on Primary Mediastinal Large B-Cell, Diffuse Large B-Cell, and Gray Zone Lymphomas: Early-Phase Treatment Findings

2017 ASH Annual Meeting
Tweet this page

Jakub Svoboda, MD, of the Abramson Cancer Center, University of Pennsylvania, discusses some encouraging phase I/II results on brentuximab vedotin with R-CHP chemotherapy as front-line treatment of CD30-positive primary mediastinal large B-cell, diffuse large B-cell, and gray zone lymphomas (Abstract 191).

Advertisement

Advertisement



Advertisement